Imatinib mesylate 600 mg

DRUG2 trials

Sponsors

Poitiers University Hospital

Conditions

Chronic Myeloid Leukemia

Phase 1

Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients

TerminatedNCT00219765

Poitiers University HospitalChronic Myeloid Leukemia

Start: 2001-05-31End: 2006-01-31Target: 30Updated: 2005-11-28

Phase 3

STI571 ProspectIve RandomIzed Trial: SPIRIT

CompletedNCT00219739

Poitiers University HospitalChronic Myeloid Leukemia

Start: 2003-09-30End: 2014-12-31Updated: 2020-04-13

Related Papers

Molecular landscape and clonal evolution in minor versus major BCR::ABL1 chronic myeloid leukemia under tyrosine kinase inhibition : A Study from the french group fi-LMC

Blood2025-11-03

Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: results of the AFR04 study.

2012-09-1721 citations

The addition of daunorubicin to imatinib mesylate in combination with cytarabine improves the response rate and the survival of patients with myeloid blast crisis chronic myelogenous leukemia (AFR01 study).

2010-12-1031 citations

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia.

2010-12-01268 citations